Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNMT1 | P26358 | 6/20 | 0.57 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.57 |
| ▸ | DNMT3B | Q9UBC3 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | PNP | P00491 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.45 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | FPR2 | P25090 | 1/20 | 0.45 |
| ▸ | TK1 | P04183 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25492471 | 1.00 | DNMT1 (0.57) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL5983092 | 1.00 | DNMT1 (0.57) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL442211 | 1.00 | DNMT1 (0.57) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL149389 | 1.00 | DNMT1 (0.57) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL23523712 | 0.96 | DNMT1 (0.53) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL27171596 | 0.89 | DNMT1 (0.57) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL7222104 | 0.88 | DNMT1 (0.56) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL9840726 | 0.88 | DNMT1 (0.56) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL7222108 | 0.88 | DNMT1 (0.56) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 | |
| SCHEMBL8755221 | 0.88 | DNMT1 (0.56) | DNMT1ADRB1DNMT3BLMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1634888-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2006-03-15 | — | — | EP | disclosed |
| EP-1600452-A2 | Synthesis of 2'-deoxy-L-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| EP-1600451-A2 | Synthesis of 2'-deoxy-l-nucleosides | Pharmasset Limited (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | PHARMASSET, INC. | 2005-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090660-A1 | 2'-deoxy-L-nucleosides | CCNH, ADAR, NSUN2 | DNMT1 692/4885ADRB1 1336/4885DNMT3B 862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.